COMPANY
Orano med
Timeline
- Trial start Phase 2: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients source ↗
- Trial start 1: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET source ↗
- Trial start Phase 1: Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05153772 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | Phase 2 | Active, not recruiting | Dec 21, 2021 | Apr 14, 2025 (actual) |
| NCT03466216 | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET | 1 | Terminated | Feb 5, 2018 | Apr 6, 2023 (actual) |
| NCT01384253 | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | Phase 1 | Completed | 2011-07 | 2015-10 (actual) |